Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer To Highlight Full Menu Of Centaur Hepatitis Automated Assays At AACC

This article was originally published in The Gray Sheet

Executive Summary

Bayer Diagnostics will unveil clinical trial data from a PMA submission for two recently approved hepatitis B assays at the American Association for Clinical Chemistry annual meeting in Orlando July 24-28

You may also be interested in...



Bayer Nabs Approval For “Fully Automated” HIV Antibody Test

Bayer is stressing the productivity advantages of its newly approved EHIV diagnostic, which the company says is the first fully automated antibody test for HIV

Bayer Nabs Approval For “Fully Automated” HIV Antibody Test

Bayer is stressing the productivity advantages of its newly approved EHIV diagnostic, which the company says is the first fully automated antibody test for HIV

Bayer Diagnostics launches compact Centaur

The firm announces FDA clearance for the Advia Centaur CP immunoassay system Nov. 21. The CP system takes up less than half the floor space as the Advia Centaur, making it appropriate for satellite and mid-sized labs, Bayer says. The platform can process 180 tests per hour, including cardiovascular, oncology, fertility and infectious disease assays. Bayer increased its total number of automated hepatitis tests to eight with the approval of two hepatitis B assays in May (1"The Gray Sheet" July 11, 2005, p. 12)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel